Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Change in Cash: 2009-2024

Historic Change in Cash for Tg Therapeutics (TGTX) over the last 16 years, with Dec 2024 value amounting to $87.0 million.

  • Tg Therapeutics' Change in Cash fell 148.74% to -$55.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$121.7 million, marking a year-over-year decrease of 370.86%. This contributed to the annual value of $87.0 million for FY2024, which is 1029.31% up from last year.
  • As of FY2024, Tg Therapeutics' Change in Cash stood at $87.0 million, which was up 1,029.31% from -$9.4 million recorded in FY2023.
  • In the past 5 years, Tg Therapeutics' Change in Cash ranged from a high of $440.8 million in FY2020 and a low of -$254.5 million during FY2021.
  • Moreover, its 3-year median value for Change in Cash was -$9.4 million (2023), whereas its average is -$39.7 million.
  • In the last 5 years, Tg Therapeutics' Change in Cash slumped by 157.75% in 2021 and then spiked by 1,029.31% in 2024.
  • Tg Therapeutics' Change in Cash (Yearly) stood at $440.8 million in 2020, then crashed by 157.75% to -$254.5 million in 2021, then rose by 22.77% to -$196.6 million in 2022, then skyrocketed by 95.24% to -$9.4 million in 2023, then surged by 1,029.31% to $87.0 million in 2024.